Cognitive Profile in Adult Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparative Study With Multiple Sclerosis

IF 3.9 2区医学 Q1 CLINICAL NEUROLOGY European Journal of Neurology Pub Date : 2025-03-19 DOI:10.1111/ene.70115

Giorgia Teresa Maniscalco, Antonio Rosario Ziello, Elisa Mantovani, Alessandro Dinoto, Daniele Di Giulio Cesare, Ornella Moreggia, Maria Elena Di Battista, Sara Carta, Vanessa Chiodega, Emanuela Stoppele, Sergio Ferrari, Vincenzo Andreone, Stefano Tamburin, Sara Mariotto

{"title":"Cognitive Profile in Adult Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparative Study With Multiple Sclerosis","authors":"Giorgia Teresa Maniscalco, Antonio Rosario Ziello, Elisa Mantovani, Alessandro Dinoto, Daniele Di Giulio Cesare, Ornella Moreggia, Maria Elena Di Battista, Sara Carta, Vanessa Chiodega, Emanuela Stoppele, Sergio Ferrari, Vincenzo Andreone, Stefano Tamburin, Sara Mariotto","doi":"10.1111/ene.70115","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has emerged as an acquired immune-mediated demyelinating disorder of the central nervous system distinct from multiple sclerosis (MS). Cognitive dysfunction and related symptoms (anxiety, depression, fatigue) and their impact on quality of life (QoL) have been in-depth characterized in MS, but data in adult MOGAD patients are very preliminary.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study aims to characterize cognitive changes through an extensive cognitive battery, as well as anxiety, depression, fatigue, and QoL, in adult MOGAD compared to MS patients.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Cognitive outcomes (number of patients with abnormal scores, score severity) depression, anxiety, fatigue, and QoL were largely comparable between MOGAD and MS patients. Most cognitive outcomes were not significantly correlated with neuropsychiatric symptoms, fatigue, and QOL in MOGAD.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our study underscores the importance of cognitive and related outcomes in MOGAD patients and the need for future studies exploring their pathophysiological and cortical morphometric underpinnings and potential therapeutic approaches.</p>\n </section>\n </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"32 3","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.70115","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ene.70115","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has emerged as an acquired immune-mediated demyelinating disorder of the central nervous system distinct from multiple sclerosis (MS). Cognitive dysfunction and related symptoms (anxiety, depression, fatigue) and their impact on quality of life (QoL) have been in-depth characterized in MS, but data in adult MOGAD patients are very preliminary.

Methods

This study aims to characterize cognitive changes through an extensive cognitive battery, as well as anxiety, depression, fatigue, and QoL, in adult MOGAD compared to MS patients.

Results

Cognitive outcomes (number of patients with abnormal scores, score severity) depression, anxiety, fatigue, and QoL were largely comparable between MOGAD and MS patients. Most cognitive outcomes were not significantly correlated with neuropsychiatric symptoms, fatigue, and QOL in MOGAD.

Conclusions

Our study underscores the importance of cognitive and related outcomes in MOGAD patients and the need for future studies exploring their pathophysiological and cortical morphometric underpinnings and potential therapeutic approaches.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

髓鞘少突胶质细胞糖蛋白抗体相关疾病成年患者的认知特征：与多发性硬化症的比较研究

髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）是一种不同于多发性硬化症（MS）的获得性免疫介导的中枢神经系统脱髓鞘疾病。认知功能障碍及其相关症状（焦虑、抑郁、疲劳）及其对生活质量（QoL）的影响在MS中已经有了深入的表征，但在成人MOGAD患者中的数据非常初步。方法本研究旨在通过广泛的认知电池，以及焦虑、抑郁、疲劳和生活质量来表征成人MOGAD与MS患者的认知变化。结果MOGAD和MS患者的认知结果（异常评分患者数量、评分严重程度）、抑郁、焦虑、疲劳和生活质量在很大程度上具有可比性。大多数认知结果与MOGAD患者的神经精神症状、疲劳和生活质量无显著相关。我们的研究强调了认知和相关结果在MOGAD患者中的重要性，以及未来研究探索其病理生理和皮层形态计量基础和潜在治疗方法的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Neurology 医学-临床神经学

CiteScore

9.70

自引率

2.00%

发文量

418

审稿时长

1 months

期刊介绍： The European Journal of Neurology is the official journal of the European Academy of Neurology and covers all areas of clinical and basic research in neurology, including pre-clinical research of immediate translational value for new potential treatments. Emphasis is placed on major diseases of large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases).